View Future GrowthItaconix 過去の業績過去 基準チェック /06Itaconixの収益は年間平均-6.3%の割合で減少していますが、 Chemicals業界の収益は年間 増加しています。収益は年間2.7% 22.6%割合で 増加しています。主要情報-6.34%収益成長率6.66%EPS成長率Chemicals 業界の成長4.35%収益成長率22.57%株主資本利益率-16.76%ネット・マージン-13.14%前回の決算情報31 Dec 2025最近の業績更新Reported Earnings • Mar 27Full year 2025 earnings released: US$0.10 loss per share (vs US$0.14 loss in FY 2024)Full year 2025 results: US$0.10 loss per share (improved from US$0.14 loss in FY 2024). Revenue: US$10.5m (up 61% from FY 2024). Net loss: US$1.38m (loss narrowed 26% from FY 2024). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 10% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.お知らせ • Mar 11Itaconix plc to Report Fiscal Year 2025 Results on Mar 24, 2026Itaconix plc announced that they will report fiscal year 2025 results on Mar 24, 2026Reported Earnings • Sep 16First half 2025 earnings released: US$0.03 loss per share (vs US$0.076 loss in 1H 2024)First half 2025 results: US$0.03 loss per share (improved from US$0.076 loss in 1H 2024). Revenue: US$4.82m (up 73% from 1H 2024). Net loss: US$410.0k (loss narrowed 60% from 1H 2024). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 18% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.お知らせ • Sep 04Itaconix plc to Report First Half, 2025 Results on Sep 15, 2025Itaconix plc announced that they will report first half, 2025 results on Sep 15, 2025Reported Earnings • Mar 31Full year 2024 earnings released: US$0.001 loss per share (vs US$0.12 loss in FY 2023)Full year 2024 results: US$0.001 loss per share. Revenue: US$6.50m (down 17% from FY 2023). Net loss: US$1.87m (loss widened 21% from FY 2023). Revenue is expected to fall by 149% p.a. on average during the next 2 years compared to a 2.4% decline forecast for the Chemicals industry in the United Kingdom.お知らせ • Mar 18Itaconix plc to Report Fiscal Year 2024 Results on Mar 31, 2025Itaconix plc announced that they will report fiscal year 2024 results on Mar 31, 2025すべての更新を表示Recent updatesReported Earnings • Mar 27Full year 2025 earnings released: US$0.10 loss per share (vs US$0.14 loss in FY 2024)Full year 2025 results: US$0.10 loss per share (improved from US$0.14 loss in FY 2024). Revenue: US$10.5m (up 61% from FY 2024). Net loss: US$1.38m (loss narrowed 26% from FY 2024). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 10% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.お知らせ • Mar 24Itaconix plc, Annual General Meeting, May 14, 2026Itaconix plc, Annual General Meeting, May 14, 2026. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdomお知らせ • Mar 11Itaconix plc to Report Fiscal Year 2025 Results on Mar 24, 2026Itaconix plc announced that they will report fiscal year 2025 results on Mar 24, 2026New Risk • Sep 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (UK£14.8m market cap, or US$19.8m).Reported Earnings • Sep 16First half 2025 earnings released: US$0.03 loss per share (vs US$0.076 loss in 1H 2024)First half 2025 results: US$0.03 loss per share (improved from US$0.076 loss in 1H 2024). Revenue: US$4.82m (up 73% from 1H 2024). Net loss: US$410.0k (loss narrowed 60% from 1H 2024). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 18% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.New Risk • Sep 15New major risk - Revenue and earnings growthEarnings have declined by 19% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 19% per year over the past 5 years. Minor Risk Market cap is less than US$100m (UK£17.5m market cap, or US$23.9m).お知らせ • Sep 04Itaconix plc to Report First Half, 2025 Results on Sep 15, 2025Itaconix plc announced that they will report first half, 2025 results on Sep 15, 2025お知らせ • Jul 02Itaconix plc Announces the Commercial Product Launch of BIO*AsterixItaconix plc announced the commercial product launch of BIOAsterix®?, a new line of plant-based functional building blocks for polymeric binders used in paints, coatings, and adhesives. The BIOAsterix products are specialty derivatives of itaconic acid that can fully or partially replace fossil-based acrylate, methacrylate, or styrene monomers in a wide range of resins and composites. The initial BIOAsterix offering consists of three products, including one new patented monomer, which are positioned as safer and more sustainable alternatives in the $2.6 billion market for butyl acrylates in Europe and North America. The Company plans to offer an extensive and comprehensive line of itaconate alternatives by adding additional proprietary and non-proprietary products to the BIOAsterix catalog in the future. Initial ecommerce customers are expected to come from North American academic and industry laboratories that are developing paths for safer and more sustainable polymers. The Company developed specialty itaconate derivatives that represent the beginning of a long-term growth initiative and future revenue opportunity for Itaconix. Commercial efforts over the last few years focused on specific usage with a limited number of potential customers. This new commercial product launch and use of ecommerce are expected to generate broader opportunities within the large and diverse paints and coatings segment of the acrylic acid market.お知らせ • May 05Itaconix plc, Annual General Meeting, May 08, 2025Itaconix plc, Annual General Meeting, May 08, 2025. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United KingdomNew Risk • Apr 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$0 net loss next year). Share price has been volatile over the past 3 months (7.3% average weekly change). Market cap is less than US$100m (UK£15.5m market cap, or US$20.3m).Reported Earnings • Mar 31Full year 2024 earnings released: US$0.001 loss per share (vs US$0.12 loss in FY 2023)Full year 2024 results: US$0.001 loss per share. Revenue: US$6.50m (down 17% from FY 2023). Net loss: US$1.87m (loss widened 21% from FY 2023). Revenue is expected to fall by 149% p.a. on average during the next 2 years compared to a 2.4% decline forecast for the Chemicals industry in the United Kingdom.New Risk • Mar 30New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Currently unprofitable and not forecast to become profitable next year (US$0 net loss next year). Market cap is less than US$100m (UK£15.1m market cap, or US$19.6m).お知らせ • Mar 18Itaconix plc to Report Fiscal Year 2024 Results on Mar 31, 2025Itaconix plc announced that they will report fiscal year 2024 results on Mar 31, 2025お知らせ • Oct 16Itaconix plc Announces Launch of the Itaconix SPARX ProgramItaconix plc announced the launch of its SPARX program - a new collaborative initiative to increase the value and reduce the time-to-market for safer, better performing, and more sustainable home and personal care products. Itaconix developed the SPARX program in response to brands seeking new innovations to meet consumer desires for affordable products that perform better and are better for the world. As an extension of its existing formulated solutions work, the Company sees opportunities in a series of home and personal care product categories for new offerings that deliver excellent performance while using safer ingredients, more sustainable materials, less chemicals, and less plastic. The SPARX program will integrate the efforts of Itaconix and other advanced specialty ingredient companies with innovative end-product manufacturers and purpose-driven brands to speed the introduction of new generations of consumer products. The program has a goal for brands to introduce at least 10 new products by the end of 2025. The Company expects to announce SPARX collaborations with ingredient suppliers, contract manufacturers, and brands in the coming months towards achieving this goal. SPARX is being introduced by Itaconix at the annual SEPAWA® CONGRESS being held in Berlin (16-18 October). SEPAWA® is one of the most influential annual gatherings within the European and North American home detergent and cleaning industry.New Risk • Sep 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (9.5% average weekly change). Minor Risk Market cap is less than US$100m (UK£19.8m market cap, or US$26.1m).お知らせ • Sep 02Itaconix plc to Report First Half, 2024 Results on Sep 10, 2024Itaconix plc announced that they will report first half, 2024 results on Sep 10, 2024分析記事 • Jul 31Itaconix (LON:ITX) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...お知らせ • Jul 16Itaconix plc Reiterates Earnings Guidance for the First Six Months of 2024Itaconix plc reiterated earnings guidance for the first six months of 2024. For the months, the company expected its revenue expectations of $6 million to $6.5 million and gross profit margin expectations of 36% for Fiscal Year 2024.お知らせ • Apr 30Itaconix plc Launches Two New Plant-Based Performance Ingredients for Household Detergents and CleanersItaconix plc announced the launch of two new ingredients for improving the performance of household detergent formulations. The new products represent major advances in phosphate replacement with new multi-functional performance from plant-based materials that are safe for the environment. Itaconix®? TSI®? 422 is the latest and most advanced addition to Itaconix's revolutionary line of multi-functional ingredients for eliminating the detrimental effects of hard water in detergent and industrial applications. Itaconix TSI 422 extends the performance advantages of the Itaconix TSI 322, particularly in dishwashing detergents. Major benefits include better scale inhibition and more compact dosing while maintaining high plant-based content. Itaconix®? ONZ™? 405 is a new powder version of Itaconix's innovative line of liquid plant-based ingredients that add both fast-acting odor neutralization and excellent scale inhibition to detergents and cleaners. The new powder form extends the potential for new performance claims into important consumer product categories such as powder laundry additives and plastic-free detergent concentrates.お知らせ • Apr 17Itaconix plc Provides Revenue Guidance for the Year 2024Itaconix plc provided revenue guidance for the year 2024. For the period, Company expects lower revenues due to not reaching satisfactory commercial terms with an existing North American detergent merchandizing customer following extensive negotiations.お知らせ • Apr 16Itaconix plc, Annual General Meeting, May 20, 2024Itaconix plc, Annual General Meeting, May 20, 2024, at 13:00 Coordinated Universal Time. Location: Fieldfisher LLP, 9th Floor, Riverbank House, 2 Swan Lane, London United KingdomReported Earnings • Apr 15Full year 2023 earnings released: US$0.12 loss per share (vs US$0.28 loss in FY 2022)Full year 2023 results: US$0.12 loss per share (improved from US$0.28 loss in FY 2022). Revenue: US$7.87m (up 41% from FY 2022). Net loss: US$1.54m (loss narrowed 38% from FY 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 2.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings.お知らせ • Apr 08Itaconix plc to Report Fiscal Year 2023 Results on Apr 15, 2024Itaconix plc announced that they will report fiscal year 2023 results on Apr 15, 2024New Risk • Apr 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (US$0 net loss next year). Market cap is less than US$100m (UK£26.3m market cap, or US$33.1m).New Risk • Mar 30New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (US$0 net loss next year). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (UK£35.3m market cap, or US$44.6m).分析記事 • Feb 28Companies Like Itaconix (LON:ITX) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...お知らせ • Feb 09Itaconix plc Appoints Jonathan Brooks as Independent Non-Executive DirectorItaconix plc announced the appointment of Jonathan Brooks to the Board as an independent Non-Executive Director. Jonathan is recently retired from the European law firm Fieldfisher LLP where he was a Partner in its highly regarded Equity Capital Markets practice. Prior to joining Fieldfisher, he was a Partner and Head of the Capital Markets Group at Maclay Murray & Spens LLP, having qualified as a solicitor and subsequently becoming a Partner at Boodle Hatfield LLP. With over 35 years of experience, Jonathan has acted for clients in a diverse range of industries, including technology, materials, healthcare, natural resources, renewable energy, and financial services. His experience extends across key corporate growth activities, serving as a valued advisor in numerous IPOs, fundraisings, and venture capital investments. He has managed transactions and advised on legal, regulatory, corporate governance and sustainability matters for a range of high-growth companies in the global equity capital markets.お知らせ • Dec 07Itaconix plc Provides Earning Guidance for the Year 2023 , Fiscal Year 2024 and for Fiscal Year 2025Itaconix plc provided earning guidance for the Year 2023, Fiscal Year 2024 and for Fiscal year 2025. For the year 2023 company expects revenues to be at least $7.7 Million, with Fiscal year 2023 earnings expected to be in line with current market expectations.For the Fiscal year 2024, revenue expectations are revised to $9.5 Million or more For the fiscal year 2025, company expects revenue of $12.5 Million or more, with no change to earnings expectations.分析記事 • Sep 23We're Hopeful That Itaconix (LON:ITX) Will Use Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, although...Reported Earnings • Sep 17First half 2023 earnings released: US$0.054 loss per share (vs US$0.13 loss in 1H 2022)First half 2023 results: US$0.054 loss per share (improved from US$0.13 loss in 1H 2022). Revenue: US$4.03m (up 32% from 1H 2022). Net loss: US$694.0k (loss narrowed 38% from 1H 2022). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 6.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.お知らせ • Sep 05Itaconix plc to Report First Half, 2023 Results on Sep 12, 2023Itaconix plc announced that they will report first half, 2023 results on Sep 12, 2023New Risk • Jun 12New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$775k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$278k free cash flow). Negative equity (-US$775k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$697k net loss in 3 years). Shareholders have been diluted in the past year (50% increase in shares outstanding). Market cap is less than US$100m (UK£31.0m market cap, or US$39.0m).Reported Earnings • Jun 05Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2022 results: US$0.50 loss per share (further deteriorated from US$0.001 loss in FY 2021). Revenue: US$5.60m (up 116% from FY 2021). Net loss: US$2.46m (loss widened 441% from FY 2021). Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) exceeded analyst estimates by 2.9%. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 6.6% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 245 percentage points per year, which is a significant difference in performance.お知らせ • May 25+ 1 more updateItaconix plc, Annual General Meeting, Jun 28, 2023Itaconix plc, Annual General Meeting, Jun 28, 2023, at 10:00 Coordinated Universal Time. Location: At the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London London United Kingdomお知らせ • Feb 03+ 1 more updateItaconix plc, Annual General Meeting, Feb 22, 2023Itaconix plc, Annual General Meeting, Feb 22, 2023, at 11:00 Coordinated Universal Time. Location: offices of Fieldfisher LLP at Riverbank House, 2 Swan Lane :London United Kingdom Agenda: To allot Ordinary Shares and to grant rights to subscribe for or to convert any security into Ordinary Shares up to an aggregate nominal amount of £8,203,187.39; to grant the Directors authority to allot equity securities under the authority given by resolution 1 for cash free of the statutory pre-emption rights which would otherwise apply, such authority to be limited; to consider Directors be authorised in addition to any authority granted under resolution 2 to allot equity securities for cash free of statutory pre-emption rights.お知らせ • Jan 05Itaconix plc Announces Board ChangesItaconix plc announced changes to the Board. Paul LeBlanc is appointed to the Board as an independent Non-Executive Director and Chair of the Audit Committee with effect from January 5, 2023. He is Chief Financial Officer and Treasurer of Bemis Associates Inc, a global manufacturer of specialty films and adhesives for the apparel and industrial markets. He joined Bemis in 1999 as Controller and assumed increasing levels of responsibility during Bemis' rapid growth into a global manufacturer, including overseeing the acquisition and integration of operations in Europe and Asia. He earned his Bachelor of Science in Accounting from Thomas College and his Master of Business Administration from University of Massachusetts, Dartmouth. In addition, Dr. Peter Nieuwenhuizen, the Company's Non-Executive Interim Chair, who joined the Board in July 2022, now takes the role of Non-Executive Chair on a permanent basis and with effect from January 5, 2023. The Board now comprises Dr. Peter Nieuwenhuizen (Non-Executive Chair), Paul LeBlanc (Non-Executive Director), John R. Shaw (Chief Executive Officer), and Laura Denner (Chief Financial Officer).Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Nee Baiz Gmunder was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Oct 27Companies Like Itaconix (LON:ITX) Are In A Position To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Reported Earnings • Sep 15First half 2022 earnings released: US$0.003 loss per share (vs US$0 in 1H 2021)First half 2022 results: US$0.003 loss per share (further deteriorated from US$0 in 1H 2021). Revenue: US$3.06m (up 124% from 1H 2021). Net loss: US$1.12m (loss widened US$941.0k from 1H 2021). Revenue is forecast to grow 43% p.a. on average during the next 2 years, compared to a 8.0% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has only increased by 38% per year, which means it is significantly lagging earnings growth.Board Change • Jul 24Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Nee Baiz Gmunder was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Breakeven Date Change • Jun 09The analyst covering Itaconix previously expected the company to break even in . New forecast suggests the company will make a profit of US$0 in .Reported Earnings • Jun 09Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: US$0.001 loss per share (up from US$0.005 loss in FY 2020). Revenue: US$2.60m (down 21% from FY 2020). Net loss: US$455.0k (loss narrowed 72% from FY 2020). Revenue exceeded analyst estimates by 6.1%. Earnings per share (EPS) also surpassed analyst estimates by 66%. Over the next year, revenue is forecast to grow 81% compared to a 15% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.Board Change • May 31High number of new directorsIndependent Non-Executive Director Nee Baiz Gmunder was the last director to join the board, commencing their role in 2022.Board Change • Apr 27High number of new directorsIndependent Non-Executive Director Nee Baiz Gmunder was the last director to join the board, commencing their role in 2022.分析記事 • Mar 30Is Itaconix (LON:ITX) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Board Change • Mar 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. CEO & Director John Shaw was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 03Itaconix plc Announces Retirement of Mike Townend as A Non-Executive DirectorItaconix plc announced that Mike Townend stepped down as a Non-Executive Director after many years of dedicated service to the Company.お知らせ • Jul 18+ 1 more updateItaconix plc announced that it has received $0.425656 million in fundingOn July 16, 2020, Itaconix plc (AIM:ITX) closed the transaction.収支内訳Itaconix の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史AIM:ITX 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 2510-14030 Sep 2510-14030 Jun 259-14031 Mar 258-24031 Dec 247-24030 Sep 247-24030 Jun 247-24031 Mar 247-24031 Dec 238-24030 Sep 237-24030 Jun 237-24031 Mar 236-24031 Dec 226-24030 Sep 225-23030 Jun 224-13031 Mar 223-13031 Dec 21303030 Sep 213-13030 Jun 214-13031 Mar 213-13031 Dec 203-22030 Sep 203-13030 Jun 20203031 Mar 202-13031 Dec 191-13030 Sep 191-54030 Jun 191-84031 Mar 191-95031 Dec 181-106030 Jun 181-146131 Mar 181-156231 Dec 171-146130 Jun 171-75231 Mar 171-65231 Dec 160-64230 Jun 16-1-42231 Mar 160-22231 Dec 150-11230 Sep 152-33330 Jun 152-323質の高い収益: ITXは現在利益が出ていません。利益率の向上: ITXは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: ITXは利益が出ておらず、過去 5 年間で損失は年間6.3%の割合で増加しています。成長の加速: ITXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: ITXは利益が出ていないため、過去 1 年間の収益成長をChemicals業界 ( -16.1% ) と比較することは困難です。株主資本利益率高いROE: ITXは現在利益が出ていないため、自己資本利益率 ( -16.76% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/08 12:31終値2026/05/08 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Itaconix plc 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Alexander BrooksCanaccord Genuity
Reported Earnings • Mar 27Full year 2025 earnings released: US$0.10 loss per share (vs US$0.14 loss in FY 2024)Full year 2025 results: US$0.10 loss per share (improved from US$0.14 loss in FY 2024). Revenue: US$10.5m (up 61% from FY 2024). Net loss: US$1.38m (loss narrowed 26% from FY 2024). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 10% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
お知らせ • Mar 11Itaconix plc to Report Fiscal Year 2025 Results on Mar 24, 2026Itaconix plc announced that they will report fiscal year 2025 results on Mar 24, 2026
Reported Earnings • Sep 16First half 2025 earnings released: US$0.03 loss per share (vs US$0.076 loss in 1H 2024)First half 2025 results: US$0.03 loss per share (improved from US$0.076 loss in 1H 2024). Revenue: US$4.82m (up 73% from 1H 2024). Net loss: US$410.0k (loss narrowed 60% from 1H 2024). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 18% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
お知らせ • Sep 04Itaconix plc to Report First Half, 2025 Results on Sep 15, 2025Itaconix plc announced that they will report first half, 2025 results on Sep 15, 2025
Reported Earnings • Mar 31Full year 2024 earnings released: US$0.001 loss per share (vs US$0.12 loss in FY 2023)Full year 2024 results: US$0.001 loss per share. Revenue: US$6.50m (down 17% from FY 2023). Net loss: US$1.87m (loss widened 21% from FY 2023). Revenue is expected to fall by 149% p.a. on average during the next 2 years compared to a 2.4% decline forecast for the Chemicals industry in the United Kingdom.
お知らせ • Mar 18Itaconix plc to Report Fiscal Year 2024 Results on Mar 31, 2025Itaconix plc announced that they will report fiscal year 2024 results on Mar 31, 2025
Reported Earnings • Mar 27Full year 2025 earnings released: US$0.10 loss per share (vs US$0.14 loss in FY 2024)Full year 2025 results: US$0.10 loss per share (improved from US$0.14 loss in FY 2024). Revenue: US$10.5m (up 61% from FY 2024). Net loss: US$1.38m (loss narrowed 26% from FY 2024). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 10% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
お知らせ • Mar 24Itaconix plc, Annual General Meeting, May 14, 2026Itaconix plc, Annual General Meeting, May 14, 2026. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom
お知らせ • Mar 11Itaconix plc to Report Fiscal Year 2025 Results on Mar 24, 2026Itaconix plc announced that they will report fiscal year 2025 results on Mar 24, 2026
New Risk • Sep 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (UK£14.8m market cap, or US$19.8m).
Reported Earnings • Sep 16First half 2025 earnings released: US$0.03 loss per share (vs US$0.076 loss in 1H 2024)First half 2025 results: US$0.03 loss per share (improved from US$0.076 loss in 1H 2024). Revenue: US$4.82m (up 73% from 1H 2024). Net loss: US$410.0k (loss narrowed 60% from 1H 2024). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 18% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
New Risk • Sep 15New major risk - Revenue and earnings growthEarnings have declined by 19% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 19% per year over the past 5 years. Minor Risk Market cap is less than US$100m (UK£17.5m market cap, or US$23.9m).
お知らせ • Sep 04Itaconix plc to Report First Half, 2025 Results on Sep 15, 2025Itaconix plc announced that they will report first half, 2025 results on Sep 15, 2025
お知らせ • Jul 02Itaconix plc Announces the Commercial Product Launch of BIO*AsterixItaconix plc announced the commercial product launch of BIOAsterix®?, a new line of plant-based functional building blocks for polymeric binders used in paints, coatings, and adhesives. The BIOAsterix products are specialty derivatives of itaconic acid that can fully or partially replace fossil-based acrylate, methacrylate, or styrene monomers in a wide range of resins and composites. The initial BIOAsterix offering consists of three products, including one new patented monomer, which are positioned as safer and more sustainable alternatives in the $2.6 billion market for butyl acrylates in Europe and North America. The Company plans to offer an extensive and comprehensive line of itaconate alternatives by adding additional proprietary and non-proprietary products to the BIOAsterix catalog in the future. Initial ecommerce customers are expected to come from North American academic and industry laboratories that are developing paths for safer and more sustainable polymers. The Company developed specialty itaconate derivatives that represent the beginning of a long-term growth initiative and future revenue opportunity for Itaconix. Commercial efforts over the last few years focused on specific usage with a limited number of potential customers. This new commercial product launch and use of ecommerce are expected to generate broader opportunities within the large and diverse paints and coatings segment of the acrylic acid market.
お知らせ • May 05Itaconix plc, Annual General Meeting, May 08, 2025Itaconix plc, Annual General Meeting, May 08, 2025. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom
New Risk • Apr 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$0 net loss next year). Share price has been volatile over the past 3 months (7.3% average weekly change). Market cap is less than US$100m (UK£15.5m market cap, or US$20.3m).
Reported Earnings • Mar 31Full year 2024 earnings released: US$0.001 loss per share (vs US$0.12 loss in FY 2023)Full year 2024 results: US$0.001 loss per share. Revenue: US$6.50m (down 17% from FY 2023). Net loss: US$1.87m (loss widened 21% from FY 2023). Revenue is expected to fall by 149% p.a. on average during the next 2 years compared to a 2.4% decline forecast for the Chemicals industry in the United Kingdom.
New Risk • Mar 30New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Currently unprofitable and not forecast to become profitable next year (US$0 net loss next year). Market cap is less than US$100m (UK£15.1m market cap, or US$19.6m).
お知らせ • Mar 18Itaconix plc to Report Fiscal Year 2024 Results on Mar 31, 2025Itaconix plc announced that they will report fiscal year 2024 results on Mar 31, 2025
お知らせ • Oct 16Itaconix plc Announces Launch of the Itaconix SPARX ProgramItaconix plc announced the launch of its SPARX program - a new collaborative initiative to increase the value and reduce the time-to-market for safer, better performing, and more sustainable home and personal care products. Itaconix developed the SPARX program in response to brands seeking new innovations to meet consumer desires for affordable products that perform better and are better for the world. As an extension of its existing formulated solutions work, the Company sees opportunities in a series of home and personal care product categories for new offerings that deliver excellent performance while using safer ingredients, more sustainable materials, less chemicals, and less plastic. The SPARX program will integrate the efforts of Itaconix and other advanced specialty ingredient companies with innovative end-product manufacturers and purpose-driven brands to speed the introduction of new generations of consumer products. The program has a goal for brands to introduce at least 10 new products by the end of 2025. The Company expects to announce SPARX collaborations with ingredient suppliers, contract manufacturers, and brands in the coming months towards achieving this goal. SPARX is being introduced by Itaconix at the annual SEPAWA® CONGRESS being held in Berlin (16-18 October). SEPAWA® is one of the most influential annual gatherings within the European and North American home detergent and cleaning industry.
New Risk • Sep 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (9.5% average weekly change). Minor Risk Market cap is less than US$100m (UK£19.8m market cap, or US$26.1m).
お知らせ • Sep 02Itaconix plc to Report First Half, 2024 Results on Sep 10, 2024Itaconix plc announced that they will report first half, 2024 results on Sep 10, 2024
分析記事 • Jul 31Itaconix (LON:ITX) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
お知らせ • Jul 16Itaconix plc Reiterates Earnings Guidance for the First Six Months of 2024Itaconix plc reiterated earnings guidance for the first six months of 2024. For the months, the company expected its revenue expectations of $6 million to $6.5 million and gross profit margin expectations of 36% for Fiscal Year 2024.
お知らせ • Apr 30Itaconix plc Launches Two New Plant-Based Performance Ingredients for Household Detergents and CleanersItaconix plc announced the launch of two new ingredients for improving the performance of household detergent formulations. The new products represent major advances in phosphate replacement with new multi-functional performance from plant-based materials that are safe for the environment. Itaconix®? TSI®? 422 is the latest and most advanced addition to Itaconix's revolutionary line of multi-functional ingredients for eliminating the detrimental effects of hard water in detergent and industrial applications. Itaconix TSI 422 extends the performance advantages of the Itaconix TSI 322, particularly in dishwashing detergents. Major benefits include better scale inhibition and more compact dosing while maintaining high plant-based content. Itaconix®? ONZ™? 405 is a new powder version of Itaconix's innovative line of liquid plant-based ingredients that add both fast-acting odor neutralization and excellent scale inhibition to detergents and cleaners. The new powder form extends the potential for new performance claims into important consumer product categories such as powder laundry additives and plastic-free detergent concentrates.
お知らせ • Apr 17Itaconix plc Provides Revenue Guidance for the Year 2024Itaconix plc provided revenue guidance for the year 2024. For the period, Company expects lower revenues due to not reaching satisfactory commercial terms with an existing North American detergent merchandizing customer following extensive negotiations.
お知らせ • Apr 16Itaconix plc, Annual General Meeting, May 20, 2024Itaconix plc, Annual General Meeting, May 20, 2024, at 13:00 Coordinated Universal Time. Location: Fieldfisher LLP, 9th Floor, Riverbank House, 2 Swan Lane, London United Kingdom
Reported Earnings • Apr 15Full year 2023 earnings released: US$0.12 loss per share (vs US$0.28 loss in FY 2022)Full year 2023 results: US$0.12 loss per share (improved from US$0.28 loss in FY 2022). Revenue: US$7.87m (up 41% from FY 2022). Net loss: US$1.54m (loss narrowed 38% from FY 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 2.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings.
お知らせ • Apr 08Itaconix plc to Report Fiscal Year 2023 Results on Apr 15, 2024Itaconix plc announced that they will report fiscal year 2023 results on Apr 15, 2024
New Risk • Apr 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (US$0 net loss next year). Market cap is less than US$100m (UK£26.3m market cap, or US$33.1m).
New Risk • Mar 30New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (US$0 net loss next year). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (UK£35.3m market cap, or US$44.6m).
分析記事 • Feb 28Companies Like Itaconix (LON:ITX) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
お知らせ • Feb 09Itaconix plc Appoints Jonathan Brooks as Independent Non-Executive DirectorItaconix plc announced the appointment of Jonathan Brooks to the Board as an independent Non-Executive Director. Jonathan is recently retired from the European law firm Fieldfisher LLP where he was a Partner in its highly regarded Equity Capital Markets practice. Prior to joining Fieldfisher, he was a Partner and Head of the Capital Markets Group at Maclay Murray & Spens LLP, having qualified as a solicitor and subsequently becoming a Partner at Boodle Hatfield LLP. With over 35 years of experience, Jonathan has acted for clients in a diverse range of industries, including technology, materials, healthcare, natural resources, renewable energy, and financial services. His experience extends across key corporate growth activities, serving as a valued advisor in numerous IPOs, fundraisings, and venture capital investments. He has managed transactions and advised on legal, regulatory, corporate governance and sustainability matters for a range of high-growth companies in the global equity capital markets.
お知らせ • Dec 07Itaconix plc Provides Earning Guidance for the Year 2023 , Fiscal Year 2024 and for Fiscal Year 2025Itaconix plc provided earning guidance for the Year 2023, Fiscal Year 2024 and for Fiscal year 2025. For the year 2023 company expects revenues to be at least $7.7 Million, with Fiscal year 2023 earnings expected to be in line with current market expectations.For the Fiscal year 2024, revenue expectations are revised to $9.5 Million or more For the fiscal year 2025, company expects revenue of $12.5 Million or more, with no change to earnings expectations.
分析記事 • Sep 23We're Hopeful That Itaconix (LON:ITX) Will Use Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Reported Earnings • Sep 17First half 2023 earnings released: US$0.054 loss per share (vs US$0.13 loss in 1H 2022)First half 2023 results: US$0.054 loss per share (improved from US$0.13 loss in 1H 2022). Revenue: US$4.03m (up 32% from 1H 2022). Net loss: US$694.0k (loss narrowed 38% from 1H 2022). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 6.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.
お知らせ • Sep 05Itaconix plc to Report First Half, 2023 Results on Sep 12, 2023Itaconix plc announced that they will report first half, 2023 results on Sep 12, 2023
New Risk • Jun 12New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$775k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$278k free cash flow). Negative equity (-US$775k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$697k net loss in 3 years). Shareholders have been diluted in the past year (50% increase in shares outstanding). Market cap is less than US$100m (UK£31.0m market cap, or US$39.0m).
Reported Earnings • Jun 05Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2022 results: US$0.50 loss per share (further deteriorated from US$0.001 loss in FY 2021). Revenue: US$5.60m (up 116% from FY 2021). Net loss: US$2.46m (loss widened 441% from FY 2021). Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) exceeded analyst estimates by 2.9%. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 6.6% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 245 percentage points per year, which is a significant difference in performance.
お知らせ • May 25+ 1 more updateItaconix plc, Annual General Meeting, Jun 28, 2023Itaconix plc, Annual General Meeting, Jun 28, 2023, at 10:00 Coordinated Universal Time. Location: At the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London London United Kingdom
お知らせ • Feb 03+ 1 more updateItaconix plc, Annual General Meeting, Feb 22, 2023Itaconix plc, Annual General Meeting, Feb 22, 2023, at 11:00 Coordinated Universal Time. Location: offices of Fieldfisher LLP at Riverbank House, 2 Swan Lane :London United Kingdom Agenda: To allot Ordinary Shares and to grant rights to subscribe for or to convert any security into Ordinary Shares up to an aggregate nominal amount of £8,203,187.39; to grant the Directors authority to allot equity securities under the authority given by resolution 1 for cash free of the statutory pre-emption rights which would otherwise apply, such authority to be limited; to consider Directors be authorised in addition to any authority granted under resolution 2 to allot equity securities for cash free of statutory pre-emption rights.
お知らせ • Jan 05Itaconix plc Announces Board ChangesItaconix plc announced changes to the Board. Paul LeBlanc is appointed to the Board as an independent Non-Executive Director and Chair of the Audit Committee with effect from January 5, 2023. He is Chief Financial Officer and Treasurer of Bemis Associates Inc, a global manufacturer of specialty films and adhesives for the apparel and industrial markets. He joined Bemis in 1999 as Controller and assumed increasing levels of responsibility during Bemis' rapid growth into a global manufacturer, including overseeing the acquisition and integration of operations in Europe and Asia. He earned his Bachelor of Science in Accounting from Thomas College and his Master of Business Administration from University of Massachusetts, Dartmouth. In addition, Dr. Peter Nieuwenhuizen, the Company's Non-Executive Interim Chair, who joined the Board in July 2022, now takes the role of Non-Executive Chair on a permanent basis and with effect from January 5, 2023. The Board now comprises Dr. Peter Nieuwenhuizen (Non-Executive Chair), Paul LeBlanc (Non-Executive Director), John R. Shaw (Chief Executive Officer), and Laura Denner (Chief Financial Officer).
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Nee Baiz Gmunder was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Oct 27Companies Like Itaconix (LON:ITX) Are In A Position To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Reported Earnings • Sep 15First half 2022 earnings released: US$0.003 loss per share (vs US$0 in 1H 2021)First half 2022 results: US$0.003 loss per share (further deteriorated from US$0 in 1H 2021). Revenue: US$3.06m (up 124% from 1H 2021). Net loss: US$1.12m (loss widened US$941.0k from 1H 2021). Revenue is forecast to grow 43% p.a. on average during the next 2 years, compared to a 8.0% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has only increased by 38% per year, which means it is significantly lagging earnings growth.
Board Change • Jul 24Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Nee Baiz Gmunder was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Breakeven Date Change • Jun 09The analyst covering Itaconix previously expected the company to break even in . New forecast suggests the company will make a profit of US$0 in .
Reported Earnings • Jun 09Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: US$0.001 loss per share (up from US$0.005 loss in FY 2020). Revenue: US$2.60m (down 21% from FY 2020). Net loss: US$455.0k (loss narrowed 72% from FY 2020). Revenue exceeded analyst estimates by 6.1%. Earnings per share (EPS) also surpassed analyst estimates by 66%. Over the next year, revenue is forecast to grow 81% compared to a 15% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
Board Change • May 31High number of new directorsIndependent Non-Executive Director Nee Baiz Gmunder was the last director to join the board, commencing their role in 2022.
Board Change • Apr 27High number of new directorsIndependent Non-Executive Director Nee Baiz Gmunder was the last director to join the board, commencing their role in 2022.
分析記事 • Mar 30Is Itaconix (LON:ITX) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Board Change • Mar 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. CEO & Director John Shaw was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 03Itaconix plc Announces Retirement of Mike Townend as A Non-Executive DirectorItaconix plc announced that Mike Townend stepped down as a Non-Executive Director after many years of dedicated service to the Company.
お知らせ • Jul 18+ 1 more updateItaconix plc announced that it has received $0.425656 million in fundingOn July 16, 2020, Itaconix plc (AIM:ITX) closed the transaction.